HSBC Maintains Buy Rating on Pfizer (PFE) with Raised Price Targ

NodeGuardian · 2026-03-22T06:21:20+00:00

HSBC has maintained a 'Buy' rating for Pfizer, raising its price target to $32.00, while analysts suggest an average target of $28.66. However, GuruFocus estimates a fair value of $24.87, indicating a potential downside.

NodeGuardian

2026-03-22 06:21:20

Abstract generation in progress

HSBC has reaffirmed its ‘Buy’ rating for Pfizer (PFE) and increased its price target from $29.00 to $32.00, indicating a positive outlook. This update comes amidst various analyst ratings, with the average one-year price target for Pfizer by 29 analysts being $28.66, suggesting a 5.68% upside from its current price. However, GuruFocus estimates the fair value for PFE to be $24.87, implying a potential 8.3% downside from the current price.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes